信达生物(01801)发布公告，自2025年8月26日起，Stephen A.Sherwin已获委任为独立非执行董事及董事 会战略委员会之成员。 ...

格隆汇8月26日丨信达生物(01801.HK)公告，自2025年8月26日起，Stephen A.Sherwin已获委任为独立非 执行董事及董事会战略委员会成员。 ...

信達生物製藥 INNOVENT BIOLOGICS, INC. （於開曼群島註冊成立的獲豁免有限公司） 董事名單及其角色與職能 Innovent Biologics, Inc.（「本公司」）董事會（「董事會」）成員載列如下： 附註： C （相關董事會委員會主席） M （相關董事會委員會成員） 2025年8月26日 獨立非執行董事 Charles Leland Cooney博士 許懿尹女士 Gary Zieziula先生 陸舜博士 陳樹云先生 (首席獨立非執行董事) Stephen A. Sherwin 博士 董事會下轄四個董事會委員會。下表列示本公司各董事所在該等委員會的成員資 料。 | | 審核委員會 | 薪酬委員會 | 提名委員會 | 戰略委員會 | | --- | --- | --- | --- | --- | | 俞德超博士 | | | M | C | | 奚浩先生 | | | | M | | 張倩女士 | | | | M | | Charles Leland | | | | | | Cooney博士 | M | | M | M | | 許懿尹女士 | C | C | M | | | Gary Zie ...

智通财经APP讯，信达生物(01801)发布公告，自2025年8月26日起，Stephen A. Sherwin已获委任为独立 非执行董事及董事会战略委员会之成员。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 信達生物製藥 INNOVENT BIOLOGICS, INC. （於開曼群島註冊成立的有限公司） （股份代號：1801） Sherwin博士已與本公司訂立委任函，自2025年8月26日起為期三年，其後繼續有 效，直至任何一方發出至少3個月書面通知終止為止。Sherwin博士須根據本公司 組織章程大綱及細則及香港聯合交易所有限公司證券上市規則（「上市規則」）附錄 C1所載之企業管治守則於應屆股東週年大會輪值告退及重選連任。根據委任函， Sherwin博士有權收取董事袍金每年人民幣400,000元，有關金額乃由董事會根據 本公司薪酬委員會之建議，經參考其經驗及於本公司的職責以及現行市況釐定。 除上文所披露者外，於本公告日期，(i) Sherwin博士並無於本公司或其附屬公司 擔任任何其他職位；(ii) Sherwin博士於過往三年內並無在其證券在香港或海外任 何證券市場上市的任何其他公眾公司擔任任何其他董事 ...

Core Viewpoint - Innovent Biologics has received implied approval for clinical trials of the drug "IBI3032," aimed at long-term weight control for overweight or obese adults [1] Company Overview - Innovent Biologics Co., Ltd. was established in 2019 and is located in Shanghai, primarily engaged in the pharmaceutical manufacturing industry [1] - The company has a registered capital of 100 million USD and a paid-in capital of 85 million USD [1] - According to data analysis, Innovent Biologics has made one external investment, participated in one bidding project, and holds nine patents, along with 72 administrative licenses [1] - The major shareholder of Innovent Biologics is Innovent Biologics (HK) Limited, which holds 100% of the shares [1]

Core Insights - The company reported total product revenue exceeding 5.2 billion yuan in the first half of 2025, representing a year-on-year growth of over 35% [1][2] - Significant advancements in new drug development include the approval of the world's first GCG/GLP-1 dual-target drug and the first IGF-1R antibody in China, with 52 new drugs (50 of which are Class 1) currently in clinical application or above [1][2][9] Financial Performance - Total product revenue for the first half of 2025 surpassed 5.2 billion yuan, marking a growth of over 35% compared to the previous year [2] - The company has successfully launched 16 new drugs, with 6 included in the National Medical Insurance Category B [2] Product Pipeline - The company has 52 new drugs in clinical application or above, including 47 large molecule biologics and 5 small molecule chemical drugs, with a focus on innovative treatment targets such as GLP-1, PDE4, and XOI [9][13] - In the oncology sector, 4 new drugs are in Phase III clinical trials, including a potential first-in-class biosimilar of ipilimumab [13][14] Market Position - The flagship product, a PD-1 monoclonal antibody, has expanded to 8 indications since its launch in 2018, with 7 indications included in the National Medical Insurance [3][6] - The company’s second major product, a biosimilar, has shown consistent sales growth, with projected sales exceeding 2 billion yuan in 2024 [6][8] International Expansion - The company has made significant strides in internationalization, including a recent financing round raising over 4.3 billion HKD (approximately 550 million USD) to support global R&D efforts [16][17] - The company has entered into a licensing agreement for a new targeted DLL3 ADC drug, receiving an upfront payment of 80 million USD and potential milestone payments of up to 1 billion USD [17][18]

每经AI快讯，8月15日，香港交易所信息显示，贝莱德在信达生物的持股比例于8月12日从5.26%降至 4.58%。 ...

Group 1 - The core point of the news is that despite a significant rise in the Hong Kong stock market, southbound funds recorded a net sell-off of 8.277 billion HKD, indicating a potential shift in investor sentiment [1] - Southbound funds have consistently net bought Xiaomi for five consecutive days, totaling 3.31711 billion HKD, suggesting strong investor interest in the company [1] - The net buying and selling activities highlight specific stocks, with notable net purchases in companies like Innovent Biologics (709 million HKD) and Li Auto (366 million HKD), while significant net sell-offs were observed in the Tracker Fund of Hong Kong (6.85 billion HKD) and Tencent Holdings (2.5 billion HKD) [1][3] Group 2 - The data shows that Tencent Holdings experienced a 4.7% decline with a net sell-off of 1.81 billion HKD, while Alibaba saw a 6.1% drop with a net sell-off of 5.25 billion HKD [3] - The Tracker Fund of Hong Kong had a significant net sell-off of 4.6 billion HKD, indicating a bearish sentiment towards this fund [3] - In contrast, companies like Innovent Biologics and Li Auto saw positive movements, with net purchases of 709 million HKD and 1.12 billion HKD respectively, reflecting a more favorable outlook from investors [3]

Core Insights - Southbound capital recorded a total transaction of 153.78 billion HKD on August 13, with a net outflow of approximately 8.28 billion HKD [1] - The Shanghai-Hong Kong Stock Connect experienced a net outflow of about 8.46 billion HKD, while the Shenzhen-Hong Kong Stock Connect saw a net inflow of around 0.18 billion HKD [1] Group 1: Significant Net Purchases - Xinda Biologics (01801.HK) had a net purchase of 709 million HKD and saw a price increase of 8.82% [1] - Li Auto-W (02015.HK) recorded a net purchase of 367 million HKD, with a price increase of 3.30% [1] - FIT HON TENG (06088.HK) experienced a net purchase of 235 million HKD and a price increase of 11.78% [1] - Xiaomi Group-W (01810.HK) had a net purchase of 176 million HKD, with a price increase of 3.00% [2] - Guotai Junan International (01788.HK) saw a net purchase of 56.18 million HKD despite a price drop of 1.47% [3] - Kuaishou-W (01024.HK) had a net purchase of 19.30 million HKD and a price increase of 4.68% [4] Group 2: Significant Net Sales - The Yingfu Fund (02800.HK) faced a net sale of approximately 6850.25 million HKD, with a price increase of 2.35% [5] - The Hang Seng China Enterprises Index (02828.HK) had a net sale of about 2311.16 million HKD, with a price increase of 2.76% [6] - Tencent Holdings (00700.HK) recorded a net sale of approximately 250.29 million HKD, with a price increase of 4.74% [7] - Alibaba Group-W (09988.HK) experienced a net sale of about 242.99 million HKD, with a price increase of 6.09% [8]